ChemDiv plays pivotal role in the discoveries of Gwynant Therapeutics and Celyn Therapeutics
ChemDiv, a leading research organization and biotech company, recently partnered with Gwynant Therapeutics and Celyn Therapeutics in their drug discovery programs. This partnership has led to crucial discoveries in the fields of neurodegenerative diseases and cancer research.
Gwynant Therapeutics
Gwynant Therapeutics is a UK-based biotech company that focuses on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. ChemDiv collaborated with Gwynant to develop a unique inhibitor of complex I of the mitochondrial respiratory chain.
The discovery of this compound has the potential to slow down or halt the progression of neurodegenerative diseases, as the complex I enzyme produces the energy needed for neuronal function. This is a significant breakthrough in the field, as current treatments only focus on relieving symptoms.
Celyn Therapeutics
Celyn Therapeutics is a Welsh biotech company that focuses on developing treatments for cancer. In collaboration with ChemDiv, Celyn has discovered a novel inhibitor of the enzyme OGA (O-GlcNAcase), which plays a vital role in the progression of cancer.
The inhibitor discovered by Celyn and ChemDiv has exhibited potent anti-cancer activity and has the potential to be used as a therapeutic agent in the treatment of various forms of cancer.
Conclusion
ChemDiv’s partnership with Gwynant Therapeutics and Celyn Therapeutics has led to groundbreaking discoveries in the fields of neurodegenerative diseases and cancer research. The discoveries have the potential to be used as therapeutic agents in the treatment of various diseases. The partnership highlights the importance and potential of collaboration in the field of drug discovery.